Direct Peptides and the "Cut Out the Middleman" Claim

The Direct Peptides name encodes a disintermediation promise: no distributor markup, factory pricing, the source itself. In commodity retail this is a clean claim; in the research peptide tier it is structurally murky, because the tier's supply chains are mostly opaque by design — the gray market structure page maps how vials typically pass from contract manufacturers (often generic, interchangeable) through rebranding sellers to buyers, with each seller presenting as the origin. A "direct from the lab" story is cheap to print and expensive to verify; the verification, if it exists at all, sits in the paperwork.

What disintermediation genuinely saves is the distribution layer's margin — a bounded number, typically visible as the spread between catalog houses like Sigma and research-vial sellers on identical sequences in our peptide price benchmarks. What it never saves is the physical cost of synthesis, purification, and QC — the floor from cheap peptides. A "factory price" below that floor is not a bargain; it is a physics violation with a shipping confirmation.

Three checks do most of the work. First, identity: does the seller's registration, facility claim, or domain history support manufacturing, or only retail? Second, documentation: genuine manufacturers produce batch records and method-named COAs by default — the ladder on high purity peptides — because their own QC process generates them whether or not marketing asks. Third, catalog coherence: real synthesis operations have capability boundaries (sequence lengths, modifications, scales) that show up as catalog shape; infinite-variety storefronts are retail aggregations, not factories — a pattern explored on peptide synthesis company.

The same test applies to every disintermediation-branded seller in the tier; the naming family is mapped alongside Modern Peptides and others on the top companies pillar.

Step 1 — run the seven questions. For any question raised about Direct Peptides and the "Cut Out the Middleman" Claim, write one line per dimension in the table above: identity, catalog, documentation, third-party testing, price position, community record, continuity. Empty lines are findings, not failures of research — they describe exactly what the public record lacks. Step 2 — weight by evidence class. Registry records and dated documents outrank community threads; community threads outrank undated sentiment; successor claims are not evidence at all. A profile is strong when most dimensions rest on the first two classes. Step 3 — date every conclusion. This market churns: domains change hands, documentation habits drift, and a profile accurate this quarter may not be accurate in the next. Record when you checked, and re-run the checklist on ownership signals. The method itself is documented in the top peptide companies pillar; Modern Peptides and Freshness as a Marketing Claim shows the same checklist applied to a different company.

Every company profile on this site is built from the same seven dimensions. Use this table to score any peptide company — profiled here or not — before treating any single reputation claim as evidence.

Table: Parameter comparison: the seven company-evaluation dimensions — apply it to any page in this cluster.